152 related articles for article (PubMed ID: 7577342)
1. Interleukin-2 in bone marrow transplantation.
Verma UN; Charak BS; Rajagopal C; Mazumder A
Cancer Treat Res; 1995; 76():315-36. PubMed ID: 7577342
[No Abstract] [Full Text] [Related]
2. Interleukin-2 in autologous bone marrow transplantation.
Charak BS
Natl Med J India; 1993; 6(1):19-22. PubMed ID: 8453356
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy with interleukin-2 after autologous bone marrow transplantation for hematologic malignancies.
Benyunes MC; Thompson JA; York A; Buckner CD; Fefer A
Prog Clin Biol Res; 1994; 389():229-38. PubMed ID: 7700905
[No Abstract] [Full Text] [Related]
4. Treatment of a patient in a relapse after bone marrow transplantation for acute lymphoblastic leukemia with the systemic administration of allogeneic lymphokine-activated killer cells and recombinant interleukin-2.
Komori T; Sugiyama H; Ogawa H; Oka Y; Miyake S; Soma T; Tani Y; Minami Y; Kunisada K; Masaoka T
Eur J Haematol; 1989 Aug; 43(2):184-5. PubMed ID: 2792327
[No Abstract] [Full Text] [Related]
5. Cellular adoptive immunotherapy after bone marrow transplantation.
Riddell SR; Greenberg PD
Cancer Treat Res; 1995; 76():337-69. PubMed ID: 7577343
[No Abstract] [Full Text] [Related]
6. Cellular immunotherapy of cancer.
Topalian SL; Rosenberg SA
Crit Care Med; 1990 Feb; 18(2 Suppl):S144. PubMed ID: 2298029
[No Abstract] [Full Text] [Related]
7. Role of interleukin-2 activated MHC-nonrestricted lymphocytes in antileukemia activity and therapy.
Lotzová E
Leuk Lymphoma; 1992 May; 7(1-2):15-28. PubMed ID: 1472926
[TBL] [Abstract][Full Text] [Related]
8. IL-2 treatment after autologous bone marrow transplantation in poor prognosis Hodgkin's disease: defective IL-2-induced LAK activity?
Tiberghien P; Racadot E; Fest T; Lioure B; Pariset J; Delain M; Voillat L; Flesch M; Amsallem D; Plouvier E
Bone Marrow Transplant; 1991; 7 Suppl 2():145. PubMed ID: 1878686
[No Abstract] [Full Text] [Related]
9. Induction by interleukin-7 of lymphokine-activated killer activity in lymphocytes from autologous and syngeneic marrow transplant recipients before and after systemic interleukin-2 therapy.
Pavletic Z; Benyunes MC; Thompson JA; Lindgren CG; Massumoto C; Alderson MR; Buckner CD; Fefer A
Exp Hematol; 1993 Sep; 21(10):1371-8. PubMed ID: 8359237
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy with interleukin 2 with or without lymphokine-activated killer cells after autologous bone marrow transplantation for malignant lymphoma: a feasibility trial.
Benyunes MC; Higuchi C; York A; Lindgren C; Thompson JA; Buckner CD; Fefer A
Bone Marrow Transplant; 1995 Aug; 16(2):283-8. PubMed ID: 7581149
[TBL] [Abstract][Full Text] [Related]
11. Interleukin 2 immediately after autologous bone marrow transplantation for acute lymphoblastic leukemia--a phase I study.
Weisdorf DJ; Anderson PM; Blazar BR; Uckun FM; Kersey JH; Ramsay NK
Transplantation; 1993 Jan; 55(1):61-6. PubMed ID: 8420066
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-2 after autologous bone marrow transplantation as consolidative immunotherapy against minimal residual disease.
Bosly A; Brice P; Humblet Y; Doyen C; Faille A; Chatelain B; Franks C; Gisselbrecht C; Symann M
Nouv Rev Fr Hematol (1978); 1990; 32(1):13-6. PubMed ID: 2349079
[TBL] [Abstract][Full Text] [Related]
13. Lymphokine-activated killer lymphocytes: biotherapeutics clinical trials.
West WH
Immunol Ser; 1989; 48():79-92. PubMed ID: 2488327
[No Abstract] [Full Text] [Related]
14. [Reconstitution process of the immune system after human bone marrow transplantation].
Maruyama S; Shibata A
Nihon Rinsho; 1990 Sep; 48(9):1965-70. PubMed ID: 2146423
[No Abstract] [Full Text] [Related]
15. Interleukin-2 therapy after autologous bone marrow transplantation for hematologic malignancies.
Fefer A; Benyunes MC; Massumoto C; Higuchi C; York A; Buckner CD; Thompson JA
Semin Oncol; 1993 Dec; 20(6 Suppl 9):41-5. PubMed ID: 8284691
[No Abstract] [Full Text] [Related]
16. Lymphokine-activated killer lymphocytes: extramural clinical trials.
Sniecinski IJ
Immunol Ser; 1989; 48():59-77. PubMed ID: 2488326
[No Abstract] [Full Text] [Related]
17. Adoptive immunotherapy with recombinant interleukin 2, LAK and TIL.
Kurnick JT; Kradin RL
Allergol Immunopathol (Madr); 1991; 19(5):209-14. PubMed ID: 1811418
[No Abstract] [Full Text] [Related]
18. Interleukin 2 in cancer therapy.
Testa U; Montesoro E; Bulgarini D; Samoggia P; Masciulli R; Habetswallner D; Carè A; Mariani G; Giannella G; Boccoli G
Ann Ist Super Sanita; 1990; 26(3-4):283-334. PubMed ID: 2091501
[TBL] [Abstract][Full Text] [Related]
19. Clinical use of interleukin-2 in treating cancer.
Patterson DL; Wiemann MC
Indiana Med; 1991 Aug; 84(8):534-7. PubMed ID: 1918915
[No Abstract] [Full Text] [Related]
20. Interleukin-2: its rationale and role in the treatment of patients with cancer.
Rubin JT
Cancer Treat Res; 1995; 80():83-105. PubMed ID: 8821575
[No Abstract] [Full Text] [Related]
[Next] [New Search]
